PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer

Abstract High-grade serous ovarian cancers (HGSOC) represent the most common subtype of ovarian malignancies. Due to the frequency of late-stage diagnosis and high rates of recurrence following standard of care treatments, novel therapies are needed to promote durable responses. We investigated the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emily Lee, Sarah Szvetecz, Ryan Polli, Angelo Grauel, Jayson Chen, Joyce Judge, Smita Jaiswal, Rie Maeda, Stephanie Schwartz, Bernd Voedisch, Mateusz Piksa, Chietara Japutra, Lingheswar Sadhasivam, Yiqin Wang, Ana Carrion, Sinan Isim, Jinsheng Liang, Thomas Nicholson, Hong Lei, Qing Fang, Michelle Steinkrauss, Dana Walker, Joel Wagner, Viviana Cremasco, Hui Qin Wang, Giorgio G. Galli, Brian Granda, Keith Mansfield, Quincey Simmons, Andrew Anh Nguyen, Nicole Vincent Jordan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/43b3a91fdd2f4465a835393a7f3b1b6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer

Ejemplares similares